Location Directory

Clinical trials in Denver, Colorado

This page shows live ClinicalTrials.gov search results for Denver, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7459

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Alcohol Use Disorder
Interventions: LY3537031, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 25 more

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 533
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more

Conditions: Cystic Fibrosis, Parenthood Status
Interventions: Parenthood; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 18
States / cities: Birmingham, Alabama • Denver, Colorado • Evanston, Illinois + 14 more

Conditions: Soft Tissue Sarcoma
Interventions: Palifosfamide-Tris, doxorubicin, Placebo; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 73
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 65 more

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions: Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration, Trametinib dimethyl sulfoxide; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 199
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 139 more

Conditions: cGVHD
Interventions: Non-Interventional; Other
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 30 more

Conditions: Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV
Interventions: Surovatamig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 18 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 14
States / cities: La Jolla, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 4 more

Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions: Ralinepag; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more

Conditions: Urinary Incontinence, Urinary Incontinence,Stress
Interventions: Adjustable Continence Therapy for Women (ACT); Device
Lead sponsor: Uromedica; Industry
Eligibility: 22 Years and older · Female only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 5
States / cities: Denver, Colorado • Meridian, Idaho • Independence, Missouri + 2 more

Conditions: Multiple Myeloma
Interventions: Arlocabtagene Autoleucel; Biological
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 41
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 33 more

Conditions: Geographic Atrophy
Interventions: Vonaprument, Sham Administration; Drug · Other
Lead sponsor: Annexon, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 71
States / cities: Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more

Clinical trials in Denver, Colorado

Filter and sort this location

Live official records

A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Adjustable Continence Therapy (ACT) for the Treatment of Female SUI

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)